Breast Cancer | Endocrine Treatment of Metastatic Breast Cancer: New Advances; Patient Education Implications

1:05:09
 
Share
 

Manage episode 237984238 series 1464352
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.

A presentation from Dr O’Shaughnessy featuring emerging research and cases from her practice.

  • Introduction (00:00)
    • Program overview: Dr Love
  • Estrogen and Progesterone Receptors; Clinical Use of Endocrine Treatment (1:20)
  • Case: A woman in her early 60s with ER/PR-positive, HER2-negative breast cancer (BC) who experienced intolerable arthralgias with adjuvant aromatase inhibition and was switched to tamoxifen (7:08)
  • First-Line Endocrine Therapy for Metastatic Disease: Role of CDK4/6 Inhibitors (12:44)
  • Case: A woman in her mid-60s with ER/PR-positive de novo metastatic BC (mBC) who received palbociclib/letrozole (12:54)
  • Case: A woman in her mid-50s with ER/PR-positive, HER2-negative BC who developed metastatic disease after receiving 4 years of adjuvant letrozole and started treatment with ribociclib/fulvestrant (27:39)
  • Case: A woman in her early 60s who received abemaciclib/exemestane for ER/PR-positive, HER2-negative mBC to the brain and bone (33:09)
  • Second-Line Endocrine Therapy for Metastatic Disease: Role of mTOR Inhibitors (42:18)
  • Case: A woman in her late 60s with ER/PR-positive, HER2-negative mBC who received exemestane/everolimus after disease progression on a CDK4/6 inhibitor (42:26)
  • New Approaches Under Investigation (51:47)
  • Assessing and Optimizing Treatment Adherence (59:00)
  • Case: A woman in her early 30s with ER/PR-positive, HER2-negative BC who demonstrated poor adherence to adjuvant endocrine therapy because of weight gain (59:09)

Select publications

2175 episodes available. A new episode about every 0 hours averaging 74 mins duration .